UNVERIFIEDSingle SourceSTAT+: Psychedelic biotechs face scrutiny over YouTube promosStat News|3/31/2026
UNVERIFIEDSingle SourceSTAT+: Biogen to acquire immunology biotech Apellis for $5.6 billionStat News|3/31/2026
UNVERIFIEDSingle SourceSTAT+: Eli Lilly to buy Centessa Pharmaceuticals, maker of a narcolepsy drug, in $6.3B dealStat News|3/31/2026
UNVERIFIEDSingle SourceSTAT+: Over-the-top psychedelic promos could undermine the field’s drug development effortsStat News|3/31/2026
UNVERIFIEDSingle SourceSTAT+: Biogen lupus drug improves skin clearance in mid-stage studyStat News|3/30/2026
UNVERIFIEDSingle SourceSTAT+: Allogene’s off-the-shelf CAR-T is nearing an early but pivotal study readoutStat News|3/26/2026
UNVERIFIEDSingle SourceSTAT+: FDA approves Denali Therapeutics drug for Hunter syndromeStat News|3/25/2026
UNVERIFIEDSingle SourceSTAT+: Sarepta Therapeutics shares rise on early promise for rare disease drugsStat News|3/25/2026
UNVERIFIEDSingle SourceSTAT+: Gilead to acquire immunology biotech, offers lifeline to GalapagosStat News|3/24/2026
UNVERIFIEDSingle SourceSTAT+: Novartis picks up experimental breast cancer therapy for $2BStat News|3/20/2026
UNVERIFIEDSingle SourceSTAT+: Eli Lilly’s ‘triple-G’ drug leads to significant blood sugar, weight reductions in diabetes trialStat News|3/19/2026
UNVERIFIEDSingle SourceSTAT+: Six drugmakers, six months: Charting the FDA’s course in the post-Prasad eraStat News|3/19/2026
UNVERIFIEDSingle SourceSTAT+: Senator blasts GSK inhaler practices, calls for reformStat News|3/17/2026
UNVERIFIEDSingle SourceSTAT+: Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pillStat News|3/16/2026
UNVERIFIEDSingle SourceSTAT+: A top biotech VC quietly helped Epstein’s ‘great friend’ make a comebackStat News|3/11/2026
UNVERIFIEDSingle SourceSTAT+: Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trialStat News|3/9/2026
UNVERIFIEDSingle SourceVinay Prasad, key Makary ally and a focus of controversy at the FDA, is leaving the agencyStat News|3/6/2026
UNVERIFIEDSingle SourceOpinion: AI could revolutionize antibiotics — but the market is standing in the wayStat News|3/5/2026
UNVERIFIEDSingle SourceSTAT+: Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccinesStat News|3/3/2026
UNVERIFIEDSingle SourceSTAT+: Prime Medicine to seek approval for gene editing treatment after two-patient trialStat News|3/3/2026
UNVERIFIEDSingle SourceSTAT+: CMS wants more drugmakers to join Medicaid ‘most-favored nations’ pilotStat News|3/3/2026
UNVERIFIEDSingle SourceSTAT+: UniQure plans to seek approval for Huntington’s therapy still blocked by FDAStat News|3/2/2026
UNVERIFIEDSingle SourceSTAT+: Novo Nordisk strikes deal with U.S. startup to develop oral obesity, diabetes drugsStat News|2/25/2026
UNVERIFIEDSingle SourceSTAT+: New treatment approach could give IBD patients hope, and be a bonanza for drugmakersStat News|2/24/2026
UNVERIFIEDSingle SourceSTAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison studyStat News|2/23/2026
UNVERIFIEDSingle SourceSTAT+: What to expect from Gossamer Bio’s late-stage lung disease studyStat News|2/19/2026
UNVERIFIEDSingle SourceSTAT+: Biotech startup raises $175 million to advance Alzheimer’s antibody therapyStat News|2/18/2026
UNVERIFIEDSingle SourceSTAT+: The health care economy, and a surprising Humira chartStat News|2/17/2026
UNVERIFIEDSingle SourceSTAT+: FDA’s rejection of Moderna threatens to stifle broader vaccine industry Stat News|2/12/2026
UNVERIFIEDSingle SourceSTAT+: The old Vinay Prasad never left. He just changed jobsStat News|2/12/2026
UNVERIFIEDSingle SourceOpinion: My granddaughter has a rare disease. But clinical trials often exclude patients like herStat News|2/11/2026
UNVERIFIEDSingle Source3 Questions: Using AI to accelerate the discovery and design of therapeutic drugsMIT News|2/4/2026
UNVERIFIEDSingle SourceSTAT+: Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s Stat News|2/2/2026
UNVERIFIEDSingle SourceSTAT+: As its immunology work draws attention, Sanofi also pushes forward in rare diseaseStat News|2/2/2026